Wysocki 1999.

Methods	Prospective cohort study Setting: inpatients and outpatients in a large metropolitan university hospital and a Veterans Affairs hospital Country: USA Duration of follow‐up: 27 months
Participants	11 participants with VLUs Mean age: 63.5 (SD 16.2) years Sex (M:F): 8:3 Exclusion criteria: fluid collected only from ulcers with no sign or symptom of clinical wound infection
Prognostic factors	uPA and MMP‐9 (continuous data); protein expression. Measurement method: fluorogenic substrate assay and fibrin overlap assay (uPA) and gelatin zymography (MMP‐9): Spectrozyme PL assay, with bovine plasminogen and 6‐aminohexanoic acid to increase sensitivity; plasmin‐specific amidolytic chromogenic substrate, free p‐nitroaniline from the substrate measured spectophotometrically. Also fibrin overlap assay to distinguish active uPA Time of measurement: baseline, and 3, 5, 16, 26, 27 months (data/gel image for 1 participant) Wound fluid sampling method: occlusive dressings (semiocclusive polyurethane film dressing placed over wound for 4‐12 hours (but usually 1‐3 hours sufficient))
Notes	Minimal data collection because no results. Risk of bias assessments available on request

ABPI: ankle‐brachial pressure index; AUR: allantoin to uric acid ratio; A‐V: arterial‐venous; CEAP: classification system for venous disorders based on their clinical, aetiological, anatomical and pathophysiological characteristics; CI: confidence interval; CVLU: chronic venous leg ulcer; DHA: docosahexaenoic acid; DVT: deep vein thrombosis; ELISA: enzyme‐linked immunosorbent assay; ELTABA: enzyme activity assay; EPA: n‐3 eicosapentaenoic acid; F: female; HR: hazard ratio; IPD: individual participant data; IQR: interquartile range; ORC: oxidised regenerated cellulose; M: male; MMP: matrix metalloproteinase; PAI‐1: plasminogen activator inhibitor‐1; PAI‐2: plasminogen activator inhibitor‐2; RCT: randomised controlled trial; RR: risk ratio; SD: standard deviation; SDS: sodium dodecyl sulphate; SE: standard error; SMD: standardised mean difference; TIMP: tissue inhibitors of metalloproteinases; uPA: urokinase‐type plasminogen activator; VLU: venous leg ulcer; WHO: World Health Organization.